AnaptysBio, Inc.
ANABNext catalyst
Quimilza
generalized pustular psoriasis (GPP)
Get an email about ANAB's next catalysts
Track AnaptysBio (ANAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ANAB Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $0.41 | FQ end Sep/2026 | Call: tbd
FDA PDUFA Date Quimilza
For generalized pustular psoriasis (GPP). Extracted from SEC filing: EX-99.1
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rosnilimab | Phase 2 | Rheumatoid Arthritis | - | - |
Etokimab | Phase 2 | Chronic Rhinosinusitis | - | - |
Rheumatoid Arthritis
1 drug in this indication
Chronic Rhinosinusitis
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in AnaptysBio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in AnaptysBio, Inc.'s (ANAB) pipeline across Phase 2. Its lead program is Etokimab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AnaptysBio, Inc.'s next FDA catalyst?→
AnaptysBio, Inc.'s (ANAB) next tracked catalyst is a PDUFA date expected Dec 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANAB biotech catalysts?→
Add ANAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AnaptysBio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.